Have a specific question about your LBP project? Click below and let’s get started.
Cell Stem Cell
Chen, X;Deng, H;Churchill, MJ;Luchsinger, LL;Du, X;Chu, TH;Friedman, RA;Middelhoff, M;Ding, H;Tailor, YH;Wang, ALE;Liu, H;Niu, Z;Wang, H;Jiang, Z;Renders, S;Ho, SH;Shah, SV;Tishchenko, P;Chang, W;Swayne, TC;Munteanu, L;Califano, A;Takahashi, R;Nagar, KK;R
Myeloid-biased hematopoietic stem cells (MB-HSCs) play critical roles in recovery from injury, but little is known about how they are regulated within the bone marrow niche. Here we describe an auto-/paracrine physiologic circuit that controls quiescence of MB-HSCs and hematopoietic progenitors marked by histidine decarboxylase (Hdc). Committed Hdc+ myeloid cells lie in close anatomical proximity to MB-HSCs and produce histamine, which activates the H2 receptor on MB-HSCs to promote their quiescence and self-renewal. Depleting histamine-producing cells enforces cell cycle entry, induces loss of serial transplant capacity, and sensitizes animals to chemotherapeutic injury. Increasing demand for myeloid cells via lipopolysaccharide (LPS) treatment specifically recruits MB-HSCs and progenitors into the cell cycle; cycling MB-HSCs fail to revert into quiescence in the absence of histamine feedback, leading to their depletion, while an H2 agonist protects MB-HSCs from depletion after sepsis. Thus, histamine couples lineage-specific physiological demands to intrinsically primed MB-HSCs to enforce homeostasis.